BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Busacca, Sara ^a   Chacko, Alex D ^b   Klabatsa, Astero ^c   Arthur, Kenneth ^b   Sheaff, Michael ^d   Gunasekharan, Vignesh K ^e   Gorski, Julia J ^b   El Tanani, Mohamed ^b   Broaddus, V Courtney ^f   Gaudino, Giovanni ^g   Fennell, Dean A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BARTS HEALTH NHS TRUST   (United Kingdom)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MYC PROTEIN; PROTEIN BAK; PROTEIN NOXA;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MITOCHONDRION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BORONIC ACIDS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; MICE; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES; TRANSCRIPTION, GENETIC;

EID: 84878768307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065489     Document Type: Article

References (47)

1. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J, (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5: 136-147.
2. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
4. Fennell DA, Rudd RM, (2004) Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 5: 354-362.
5. Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, et al. (2008) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol 61: 549-558.
6. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, et al. (2007) Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13: 5942-5951.
7. Fennell DA, McDowell C, Busacca S, Webb G, Moulton B, et al. (2012) Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. J Thorac Oncol 7: 1466-1470.
8. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, et al. (2008) Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 6: 755-760.
9. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C, (2008) Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 103: 270-283.
10. Lu S, Chen Z, Yang J, Chen L, Gong S, et al. (2008) Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 36: 1278-1284.
11. Lu S, Yang J, Chen Z, Gong S, Zhou H, et al. (2009) Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 37: 831-837.
12. Lu S, Yang J, Song X, Gong S, Zhou H, et al. (2008) Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 326: 423-431.
13. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499.
14. Voortman J, Checinska A, Giaccone G, (2007) The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer 6: 73.
15. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, et al. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 106: 2200-2205.
16. Rzymski T, Milani M, Singleton DC, Harris AL, (2009) Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8: 3838-3847.
17. Fennell DA, Chacko A, Mutti L, (2008) BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27: 1189-1197.
18. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, et al. (1994) Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57: 1395-1401.
19. Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, et al. (1991) Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 47: 285-290.
20. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, et al. (2003) BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 300: 135-139.
21. Swift S, Lorens J, Achacoso P, Nolan GP (2001) Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol Chapter 10: Unit 10 17C.
22. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, et al. (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293.
23. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, et al. (2007) Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99: 1683-1694.
24. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, et al. (2007) Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 104: 19488-19493.
25. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, et al. (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8: 2505-2511.
26. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, et al. (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24: 5025-5033.
27. Scagliotti GV, Germonpre P, Bosquee L, Vansteenkiste J, Gervais R, et al. (2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68: 420-426.
28. Du X, Youle RJ, FitzGerald DJ, Pastan I, (2010) Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol 30: 3444-3452.
29. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, et al. (2003) The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22: 4953-4963.
30. Willis SN, Chen L, Dewson G, Wei A, Naik E, et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
31. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, et al. (2006) Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol 45: 449-453.
32. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, et al. (1999) Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5: 3508-3515.
33. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
34. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, et al. (2005) Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65: 6294-6304.
35. Ri M, Iida S, Ishida T, Ito A, Yano H, et al. (2008) Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci.
36. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058.
37. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, et al. (2008) Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 7: 50.
38. Pandit B, Gartel AL, (2011) Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am J Pathol 178: 355-360.
39. Liu W, Swetzig WM, Medisetty R, Das GM, (2011) Estrogen-mediated upregulation of Noxa is associated with cell cycle progression in estrogen receptor-positive breast cancer cells. PLoS One 6: e29466.
40. Pietruska JR, Kane AB, (2007) SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 67: 3637-3645.
41. Ehebauer M, Hayward P, Arias AM, (2006) Notch, a universal arbiter of cell fate decisions. Science 314: 1414-1415.
42. Xiong H, Chen ZF, Liang QC, Du W, Chen HM, et al. (2009) Inhibition of DNA methyltransferase induces G2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5 signalling. J Cell Mol Med 13: 3668-3679.
43. Brenner C, Deplus R, Didelot C, Loriot A, Vire E, et al. (2005) Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 24: 336-346.
44. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
45. McMahon SB, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD, (1998) The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94: 363-374.
46. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia.
47. Busse A, Kraus M, Na IK, Rietz A, Scheibenbogen C, et al. (2008) Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 112: 659-670.